Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line

Daratumumab is a new drug for the treatment of multiple myeloma (Kahler disease). The drug acts by targeting some specific cells that destroys the cancer cells and also improve the body’s natural immune response. The safety and efficacy of daratumumab is currently being evaluated for use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy and autologous stem cell transplant